Lowest Price Guaranteed From USD 4,799
Published
August 2023
Slides
170
View Count
8587
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global RNA Vaccines and RNA Therapeutics market is estimated to be worth over USD 1.1 billion in 2035 and is expected to grow at compounded annual growth rate (CAGR) of 50% during the forecast period (2026-2035). In the past few years, RNA based therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. In addition, they offer enhanced therapeutic and safety profiles as compared to traditional treatment approaches. However, there are some concerns associated with the highly unstable nature of such molecules and their delivery at adequate concentrations. Therefore, in order to address the challenges pertaining to the use of RNA therapeutics and RNA vaccines, several industry players have been engaged in the development / deployment of novel technologies for the design, development and manufacturing of next generation RNA-based therapeutics / vaccines, offering the healthcare sector a promising disease management recourse.
The next generation RNA therapeutics and RNA vaccines are modified treatment molecules aimed at specifically targeting and treating diseases that were earlier considered undruggable. Among these, innovative modalities, such as circular RNA (circRNA), endless RNA (eRNA), self activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA) have emerged as popular targeted therapeutics. The success of these next generation RNA therapeutics and RNA vaccines can be attributed to their structural stability, expression specificity, targeted delivery, non-immunogenic nature, high efficiency and ability to target a wide range of therapeutic modalities, including influenza, COVID-19 infection, breast cancer and interstitial lung disease, among others. Further, owing to their self-replicating nature, such RNA based therapeutics offer prolonged therapeutic effects at relatively low and less frequent doses, as compared to traditional methods.
Given the ongoing pace of innovation in this field, encouraging clinical trial results, accelerated approvals, and the continuous efforts of both industry and non-industry players, the next generation RNA vaccines and RNA therapeutics market is likely to witness significant growth during the forecast period.
The RNA Vaccines and RNA Therapeutics Market: Distribution by Type of Modality (RNA Therapeutics and RNA Vaccines), Type of Molecule (replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA), Therapeutic Areas (Infectious Diseases, Oncological Disorders and Pulmonary Disorders), Route of Administration (Intradermal, Intramuscular and Intravenous), Key Geographical Regions (North America, Europe and Asia-Pacific) and Leading Players: Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the RNA vaccines and RNA therapeutics market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the RNA vaccines and RNA therapeutics market are briefly discussed below.
The next generation RNA vaccines and RNA therapeutics market landscape is concentrated with the presence of over 35 large, mid-sized and small companies. Of these, 50% of the companies were established during the period 2016-2020, indicating significant start-up activity in this therapeutic market segment. Examples of companies (established in 2019 and 2020, in alphabetical order) include Chimerna Therapeutics, Orna Therapeutics, Replicate Bioscience, Transine Therapeutics, VaxEquity, VLP Therapeutics and Ziphius Vaccines. Further, more than 70% of the companies are based in North America. Within Europe, the UK has emerged as the hub of players engaged in the development of next generation RNA therapeutics and RNA vaccines.
It is worth mentioning that, currently, over 100 next generation RNA therapeutics and RNA vaccines are either approved or being evaluated in various stages of development; of these, nearly 25% of the drug candidates are being evaluated in clinical trials. Further, 40% and 32% of the drug candidates are being investigated for the treatment of infectious diseases and oncological disorders, respectively, across different phases of development. These drug candidates have emerged as popular targeted therapy among therapy developers.
Recent advancements in the healthcare industry in the last few years have led to the development of various novel drug modalities. Interestingly, the industry is evaluating next generation RNA therapeutics and RNA vaccines, which have surfaced as possible targeted therapies for a wide range of therapeutic indications.
It is important to highlight that a therapeutic modality, ATYR1923, developed by aTyr Pharma, is currently being investigated in phase III, targeting Pulmonary Sarcoidosis. Recently, in August 2022, the drug received fast track designation from the USFDA. Over 1,160 clinical trial initiatives focused on various next generation drug modalities, such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA), long non coding RNA and others have been undertaken since 2019, indicating the substantial research efforts being made in this industry.
Since 2021, 18 clinical trials have been registered for the evaluation of next generation RNA therapeutics and vaccines. Of these, 72% of the trials were focused on infectious diseases. This can be attributed to the enhanced activity of industry players towards the development of therapies targeting COVID-19. Interestingly, 27% of these trials have advanced to the late stages of development (phase II and above). As the next generation RNA therapeutics and RNA vaccines move along the clinical development trajectory, we expect the market to grow at a favorable CAGR during the forecast period.
RNA vaccines have caught the attention of the pharmaceutical industry, specifically during the COVID-19 pandemic, when the first generation mRNA based COVID vaccine received approval from regulatory authorities. Prior to mRNA vaccines, other modalities, such as antisense RNA, siRNA and RNA aptamers were evaluated as therapeutics. Gemcovac®, developed by HDT Bio was the first self amplifying mRNA (saRNA) based COVID vaccine to receive emergency use approval in India, in June 2022. Notably, this COVID vaccine is currently being evaluated in clinical trials in the US, Brazil and South Korea. According to the pivotal trial results, Gemcovac® demonstrated a much lower rate of adverse events as compared to the COVID vaccine, developed by Moderna and Pfizer. The immunological response of the therapy was comparable to that developed by AstraZeneca. Additionally, Gemcovac® is supplied in lyophilized powder form and requires storage in a normal refrigerator. This self amplifying mRNA vaccine is delivered intradermally, unlike most of the COVID vaccines that are administered intramuscularly. Owing to their highly stable structure, enhanced therapeutic profile and low concentration administration, the next generation RNA therapeutics and RNA vaccines have emerged as a potential alternative to conventional RNA-based approaches.
Another player, Arcturus Therapeutics is developing the COVID vaccine using its proprietary self amplifying mRNA technology platform. In April 2023, its collaboration partner, Meiji Seika Pharma, submitted an NDA to commercialize the vaccine, ARCT-154, in Japan. The launch of more such self amplifying mRNA vaccines will drive the market growth over the forecast period.
The pandemic offered a major thrust to RNA-based therapies. Since then, industry stakeholders are actively being engaged in the development of therapies that are long lasting and can target a wide range of therapeutic targets, giving rise to the development of next generation RNA therapeutics and RNA vaccines using various approaches.
One such approach involves the use of transfer RNA (tRNA), being engineered by US-based Alltrna, in order to correct gene code and ultimately gene expression. The company raised USD 50 million in Series A funding in 2020. However, Alltrna is not the sole company working on tRNA technology. Other companies include ReCode Therapeutics, ShapeTX, Tevard Biosciences and hC Bioscience. The current tRNA market landscape features the presence of close to ten therapies, of which, majority are still in early stages of development. These therapies are primarily being developed to target indications, such as Cystic Fibrosis, Duchenne Muscular Dystrophy and Pulmonary Sarcoidosis.
Circular RNA is a covalently bonded closed-loop RNA structure, engineered from linear RNAs by circularization. These structures confer higher stability to the RNA molecules, protecting the molecule from rapid degradation by exonucleases. Recently, the next generation RNA therapeutics and vaccines domain has witnessed the emergence of industry players engaged in the development of circular RNA therapies, owing to the vast potential and high stability of such therapies. Examples of some players include (in alphabetical order) Chimerna Therapeutics, Esperovax, Flagship Pioneering’s Laronde, Ginkgo Bioworks, Orna Therapeutics, Ring Code Biotech, Circio and Therorna. Notably, since 2019, more than USD 380 million has been raised / invested by companies engaged in the development of circular RNA, reflecting significant funding activity for circular RNA-based therapies in this domain.
It is worth highlighting that industry players are actively collaborating with circular RNA therapy developers in order to support the discovery, development and delivery of circRNA molecules. For instance, Renagade Therapeutics has entered into a collaboration with Orna Therapeutics in order to support the delivery of circular RNA therapies being discovered by Orna Therapeutics. Considering the potential of these therapies, several industry stakeholders are actively engaging in the development of such therapeutics. The support from venture capitalists and big pharmaceutical companies will continue to drive the development of circular RNA therapeutics and market growth over the forecast period.
Many stakeholders are undertaking initiatives to forge alliances with other industry / non-industry players. Of the strategic partnerships focused on next generation RNA therapeutics and RNA vaccines that have been inked since 2019, close to 22% of partnerships are research and development agreements, indicating that the stakeholders are actively engaged in research and development of these next generation RNA therapeutics and RNA vaccines. Interestingly, it was observed that many big pharma players, such as Merck, Gilead Sciences, AstraZeneca and others have partnered with several next generation RNA therapeutics and RNA vaccines players, in order to expand their respective portfolios. It is worth highlighting that a sum of $2.9 billion has been raised / invested by players engaged in the development of RNA therapeutics and RNA vaccines, indicating the interest of stakeholders in this market.
Given the inclination towards development of novel next generation RNA therapeutics and RNA vaccines, along with the engagement of big pharma players and high investments, we believe that the next generation RNA therapeutics and RNA vaccines market is likely to evolve at a rapid pace over the forecast period.
Driven by the rising interest in R&D activities and growing demand for effective therapies for rare and oncological disorders, the next generation RNA therapeutics and RNA vaccines market is anticipated to witness an annualized growth rate (CAGR) of over 50%, during the forecast period (2026-2035). Specifically, in terms of type of molecule, the global market for next generation RNA therapeutics and RNA vaccines is anticipated to be driven by self amplifying mRNAs. Likewise, in terms of therapeutic area, the market is anticipated to be dominated by the RNA therapeutics and RNA vaccines targeting oncological disorders and pulmonary disorders.
In addition, close to 94% of the market share in 2035 is captured by the players based in North America. However, it is worth highlighting that the next generation RNA therapeutics and RNA vaccines market in Asia-Pacific is anticipated to grow at a higher CAGR, during the forecast period (2030-2035).
Recently, the increasing number of orphan and fast track designations granted by the regulatory authorities, such as the USFDA and the EMA, has intrigued interest and increased the confidence of the pharmaceutical industry in these novel targeted therapies. All the above factors will contribute to a healthy market growth of the next generation RNA therapeutics and RNA vaccines market during the forecast period.
Examples of key companies engaged in the next generation RNA therapeutics and RNA vaccines development (which have also been captured in this market report, arranged in alphabetical order) include Alphavax, Arcturus Therapeutics, Atyr Pharma, Flagship Pioneering, Forge Therapeutics, Gingko Bioworks, Gritstone Bio, HDT Bio, Laronde Therapeutics, MiNA Therapeutics, Orna Therapeutics, Recode Therapeutics, Renegade Therapeutics, Replicate Bioscience, Shape Therapeutics and VLP Therapeutics. This market report includes an easily searchable excel database of all the companies developing next generation RNA therapeutics and RNA vaccines, worldwide.
Several recent developments have taken place in the field of next generation RNA vaccines and RNA therapeutics, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table:
| Key Report Attributes | Details | |
| Bese Year | 2022 | |
| Forecast Period | 2023-2035 | |
| CAGR (2026-2035) |
~50% |
|
|
Type of Modality |
Therapeutics, Vaccines |
|
|
Type of Molecule |
|
|
|
Therapeutic Area |
|
|
|
Route of Administration |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| Customization Scope | 15% Free Customization Option | |
| PowerPoint Presentation (Complimentary) |
Available |
|
| Excel Data Packs (Complimentary) |
|
|
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the next generation RNA therapeutics and RNA vaccines over the forecast period. Based on several parameters, such as region-specific adoption rates and expected prices of such modalities, we have developed informed estimates of the likely evolution of the next generation RNA vaccines and RNA therapeutics market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (repRNA, saRNA, sacRNA, samRNA and tRNA), therapeutic area (infectious diseases, oncological disorders and pulmonary disorders), route of administration (intradermal, intramuscular and intravenous), key geographical regions (North America, Europe and Asia-Pacific) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and secondary research. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. RNA Therapeutics and RNA Vaccines Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
5.3. Types of Next Generation RNA Molecules
5.4. Key Aspects of Next Generation RNA Molecules
5.5. Key Challenges Associated with Traditional RNA Modalities
5.6. Advantages of Using Next Generation RNA Modalities
6. MARKET LANDSCAPE
6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
6.1.1. Analysis by Type of Modality
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Delivery Vehicle
6.1.4. Analysis by Phase of Development
6.1.5. Analysis by Therapeutic Area
6.1.6. Most Active Players: Analysis by Number of Therapies
6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Route of Administration
6.2.3. Analysis by Therapeutic Area
6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
6.4.1. Analysis by Phase of Development
6.4.2. Analysis by Therapeutic Area
6.4.3. Most Active Players: Analysis by Number of Therapies
6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
6.5.1. Analysis by Phase of Development
6.5.2. Analysis by Therapeutic Area
6.5.3. Most Active Players: Analysis by Number of Therapies
7. TECHNOLOGY LANDSCAPE
7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
7.1.1. Analysis by Class of Molecule
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Capabilities of the Technology
7.1.4. Analysis by Therapeutic Area
7.1.5. Analysis by Highest Phase of Development
7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Operational Model
8. DRUG PROFILES
8.1. Gemcovac
8.1.1. Developer Overview
8.1.2. Drug Overview
8.1.3. Clinical Trial Information
8.1.4. Clinical Trial Endpoints
8.1.5. Clinical Trial Results
8.1.6. Estimated Sales
8.2. ATYR1923
8.2.1. Developer Overview
8.2.2. Drug Overview
8.2.3. Clinical Trial Information
8.2.4. Clinical Trial Endpoints
8.2.5. Clinical Trial Results
8.2.6. Estimated Sales
8.3. ARCT-154
8.3.1. Developer Overview
8.3.2. Drug Overview
8.3.3. Clinical Trial Information
8.3.4. Clinical Trial Endpoints
8.3.5. Clinical Trial Results
8.3.6. Estimated Sales
8.4. GRT-C901
8.4.1. Developer Overview
8.4.2. Drug Overview
8.4.3. Clinical Trial Information
8.4.4. Clinical Trial Endpoints
8.4.5. Clinical Trial Results
8.4.6. Estimated Sales
8.5. VLPCOV-01
8.5.1. Developer Overview
8.5.2. Drug Overview
8.5.3. Estimated Sales
8.6. AVX901
8.6.1. Developer Overview
8.6.2. Drug Overview
8.6.3. Clinical Trial Information
8.6.4. Clinical Trial Endpoints
8.6.5. Clinical Trial Results
8.6.6. Estimated Sales
8.7. MTL-CEBPA + Sorafenib
8.7.1. Developer Overview
8.7.2. Drug Overview
8.7.3. Clinical Trial Information
8.7.4. Clinical Trial Endpoints
8.7.5. Clinical Trial Results
8.7.6. Estimated Sales
8.8. SLATE
8.8.1. Developer Overview
8.8.2. Drug Overview
8.8.3. Clinical Trial Information
8.8.4. Clinical Trial Endpoints
8.8.5. Clinical Trial Results
8.8.6. Estimated Sales
9. CLINICAL TRIAL ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Trial Phase
9.2.5. Analysis by Patients Enrolled
9.2.6. Analysis by Type of Sponsor
9.2.7. Analysis by Therapeutic Area
9.2.8. Analysis by Study Design
9.2.9. Leading Organizations: Analysis by Number of Trials
9.2.10. Analysis by Focus Area
9.2.11. Analysis by Geography
10. PATENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
10.2.1. Analysis by Type of Patent
10.2.2. Analysis by Patent Publication Year
10.2.3. Analysis by Patent Jurisdiction
10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
10.2.4. Analysis by CPC Symbols
10.2.5. World Cloud Analysis: Emerging Focus Areas
10.2.6. Analysis by Patent Age
10.2.7. Leading Industry Players: Analysis by Number of Patents
10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Partnership Models
11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
11.2.1. Analysis by Year of Partnership
11.2.2. Analysis by Type of Partnership
11.2.3. Analysis by Year and Type of Partnership
11.2.4. Analysis by Year and Type of Molecule
11.2.5. Analysis by Focus of Partnership
11.2.6. Analysis by Purpose of Partnership
11.2.7. Analysis by Therapeutic Area
11.2.8. Most Active Players: Analysis by Number of Partnerships
11.2.9. Analysis by Geography
11.2.9.1. Local and International Agreements
11.2.9.2. Intracontinental and Intercontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Types of Funding
12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
12.3. Analysis by Year of Funding
12.4. Analysis by Type of Funding
12.5. Analysis by Type of Molecule
12.6. Analysis of Amount Invested by Year of Funding
12.7. Analysis of Amount Invested by Type of Funding
12.8. Analysis by Geography
12.9. Analysis by Year and Type of Funding
12.10. Analysis by Purpose of Funding
12.11. Analysis by Stage of Development
12.12. Analysis by Therapeutic Area
12.13. Most Active Players: Analysis by Number of Funding Instances
12.14. Most Active Players: Analysis by Amount Invested
12.15. Leading Investors: Analysis by Number of Funding Instances
13. BIG PHARMA INITIATIVES
13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
13.1.1. Analysis by Number of Initiatives
13.1.2. Analysis by Year of Initiative
13.1.3. Analysis by Type of Initiative
13.1.3.1. Analysis by Type of Partnership
13.1.3.2. Analysis by Type of Funding
13.1.4. Analysis by Purpose of Initiative
13.1.5. Analysis by Year and Number of Initiatives
13.1.6. Analysis by Focus of Initiative
13.1.7. Analysis by Location of Headquarters of Big Pharma Players
14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035
14.1. Key Assumptions and Methodology
14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
14.2.1. Scenario Analysis
14.3. Key Market Segmentations
14.4. Dynamic Dashboard
15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY
15.1. Therapeutics: Forecasted Estimates (2023-2035)
15.2. Vaccines: Forecasted Estimates (2023-2035)
15.3. Data Triangulation and Validation
16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE
16.1. repRNA: Forecasted Estimates (2023-2035)
16.2. saRNA: Forecasted Estimates (2023-2035)
16.3. sacRNA: Forecasted Estimates (2023-2035)
16.4. sa-mRNA: Forecasted Estimates (2023-2035)
16.5. tRNA: Forecasted Estimates (2023-2035)
16.6. Data Triangulation and Validation
17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA
17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
17.4. Data Triangulation and Validation
18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.4. Data Triangulation and Validation
19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. North America: Forecasted Estimates (2023-2035)
19.1.1. US: Forecasted Estimates (2023-2035)
19.2. Europe: Forecasted Estimates (2023-2035)
19.2.1. France: Forecasted Estimates (2023-2035)
19.2.2. Italy: Forecasted Estimates (2023-2035)
19.2.3. Spain: Forecasted Estimates (2023-2035)
19.2.4. UK: Forecasted Estimates (2023-2035)
19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
19.3.1. India: Forecasted Estimates (2023-2035)
19.3.2. Japan: Forecasted Estimates (2023-2035)
19.3.3. Singapore: Forecasted Estimates (2023-2035)
19.4. Data Triangulation and Validation
20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS
20.1. Company A
20.2. Company B
20.3. Company C
20.4. Company D
20.5. Company E
21. CONCLUSION
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Overall Technology Landscape
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Partnerships and Collaborations
Figure 4.6 Executive Summary: Funding and Investment Analysis
Figure 4.7 Executive Summary: Big Pharma Initiatives
Figure 4.8 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
Figure 5.2 Key Aspects of Next Generation RNA Molecules
Figure 5.3 Key Challenges Associated with Traditional RNA Modalities
Figure 5.4 Advantages of Using Next Generation RNA Modalities
Figure 6.1 Next Generation RNA Therapies: Distribution by Type of Modality
Figure 6.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Figure 6.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Figure 6.4 Next Generation RNA Therapies: Distribution by Phase of Development
Figure 6.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Figure 6.6 Most Active Players: Distribution by Number of Therapies
Figure 6.7 Clinical Stage Therapies: Distribution by Phase of Development
Figure 6.8 Clinical Stage Therapies: Distribution by Route of Administration
Figure 6.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Figure 6.10 Therapy Developer Landscape: Distribution by Year of Establishment
Figure 6.11 Therapy Developer Landscape: Distribution by Company Size
Figure 6.12 Therapy Developer Landscape: Distribution by Location of Headquarters
Figure 6.13 circRNA Therapies: Distribution by Phase of Development
Figure 6.14 circRNA Therapies: Distribution by Therapeutic Area
Figure 6.15 Most Active Players: Distribution by Number of circRNA Therapies
Figure 6.16 saRNA Therapies: Distribution by Phase of Development
Figure 6.17 saRNA Therapies: Distribution by Therapeutic Area
Figure 6.18 Most Active Players: Distribution by Number of saRNA Therapies
Figure 7.1 Next Generation RNA Technologies: Distribution by Class of Molecule
Figure 7.2 Next Generation RNA Technologies: Distribution by Type of Molecule
Figure 7.3 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Figure 7.4 Next Generation RNA Technologies: Distribution by Therapeutic Area
Figure 7.5 Next Generation RNA Technologies: Distribution by Highest Phase of Development
Figure 7.6 Technology Developer Landscape: Distribution by Year of Establishment
Figure 7.7 Technology Developer Landscape: Distribution by Company Size
Figure 7.8 Technology Developer Landscape: Distribution by Location of Headquarters
Figure 7.9 Technology Developer Landscape: Distribution by Operational Model
Figure 8.1 Gemcovac®: Estimated Sales
Figure 8.2 ATYR1923: Estimated Sales
Figure 8.3 ARCT-154: Estimated Sales
Figure 8.4 GRT-C901: Estimated Sales
Figure 8.5 VLPCOV-01: Estimated Sales
Figure 8.6 AVX901: Estimated Sales
Figure 8.7 MTL-CEBPA + Sorafenib: Estimated Sales
Figure 8.8 SLATE: Estimated Sales
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Patients Enrolled
Figure 9.6 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 9.7 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
Figure 9.9 Leading Organizations: Distribution by Number of Trials
Figure 9.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 9.11 Clinical Trial Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 10.3 Patent Analysis: Distribution by Patent Jurisdiction
Figure 10.4 Patent Jurisdiction: North American Scenario
Figure 10.5 Patent Jurisdiction: European Scenario
Figure 10.6 Patent Jurisdiction: Aisa-Pacific Scenario
Figure 10.7 Patent Analysis: Distribution by Patent Age
Figure 10.8 Patent Analysis: Distribution by CPC Symbols
Figure 10.9 Word Cloud Analysis: Emerging Focus Areas
Figure 10.10 Leading Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.12 Patent Analysis: Distribution by Patent Characteristics
Figure 10.13 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
Figure 11.4 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
Figure 11.5 Partnerships and Collaborations: Distribution by Focus of Partnership
Figure 11.6 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Local and International Deals
Figure 11.10 Partnerships andCollaborations: Intercontinental and Intracontinental Deals
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 12.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Molecule
Figure 12.4 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.6 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 12.7 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
Figure 12.8 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 12.9 Funding and Investment Analysis: Distribution by Stage of Development
Figure 12.10 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 12.11 Most Active Players: Distribution by Number of Funding Instances
Figure 12.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 12.13 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Big Pharma Initiatives: Distribution by Number of Initiatives
Figure 13.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Figure 13.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 13.4 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
Figure 13.5 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
Figure 13.6 Big Pharma Initiatives: Distribution by Focus of Initiative
Figure 13.7 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
Figure 14.1 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), BaseScenario (USD Million)
Figure 14.2 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
Figure 14.3 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
Figure 15.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
Figure 15.2 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 15.3 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
Figure 16.2 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.3 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.4 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.5 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 16.6 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Figure 17.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
Figure 17.2 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
Figure 17.3 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
Figure 17.4 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
Figure 18.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
Figure 18.2 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Figure 18.3 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Figure 18.4 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Figure 19.2 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.3 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.4 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.5 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.6 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.7 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.8 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.9 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.10 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.11 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.12 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
Figure 19.13 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
Figure 20.1 RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)
Table 6.1 List of Next Generation RNA Therapeutics and RNA Vaccines
Table 6.2 List of Clinical Stage Next Generation RNA Therapeutics and RNA Vaccines
Table 6.3 List of Next Generation RNA Therapeutic and RNA Vaccine Developers
Table 7.1 List of Next Generation RNA Technologies
Table 7.2 List of Next Generation RNA Technology / Platform Developers
Table 8.1 Gemcovac®: Developer Overview
Table 8.2 Gemcovac®: Drug Overview
Table 8.3 Gemcovac®: Clinical Trial Information
Table 8.4 Gemcovac®: Clinical Trial Endpoints
Table 8.5 Gemcovac®: Clinical Trial Results
Table 8.6 ATYR1923: Developer Overview
Table 8.7 ATYR1923: Drug Overview
Table 8.8 ATYR1923: Clinical Trial Information
Table 8.9 ATYR1923: Clinical Trial Endpoints
Table 8.10 ATYR1923: Clinical Trial Results
Table 8.11 ARCT-154: Developer Overview
Table 8.12 ARCT-154: Drug Overview
Table 8.13 ARCT-154: Clinical Trial Information
Table 8.14 ARCT-154: Clinical Trial Endpoints
Table 8.15 ARCT-154: Clinical Trial Results
Table 8.16 GRT-C901: Developer Overview
Table 8.17 GRT-C901: Drug Overview
Table 8.18 GRT-C901: Clinical Trial Information
Table 8.19 GRT-C901: Clinical Trial Endpoints
Table 8.20 GRT-C901: Clinical Trial Results
Table 8.21 VLPCOV-01: Developer Overview
Table 8.22 VLPCOV-01: Drug Overview
Table 8.23 AVX-901: Developer Overview
Table 8.24 AVX-901: Drug Overview
Table 8.25 AVX-901: Clinical Trial Information
Table 8.26 AVX-901: Clinical Trial Endpoints
Table 8.27 AVX-901: Clinical Trial Results
Table 8.28 MTL-CEBPA + Sorafenib: Developer Overview
Table 8.29 MTL-CEBPA + Sorafenib: Drug Overview
Table 8.30 MTL-CEBPA + Sorafenib: Clinical Trial Information
Table 8.31 MTL-CEBPA + Sorafenib: Clinical Trial Endpoints
Table 8.32 MTL-CEBPA + Sorafenib: Clinical Trial Results
Table 8.33 SLATE: Developer Overview
Table 8.34 SLATE: Drug Overview
Table 8.35 SLATE: Clinical Trial Information
Table 8.36 SLATE: Clinical Trial Endpoints
Table 8.37 SLATE: Clinical Trial Results
Table 9.1 RNA Therapeutics and RNA Vaccines: List of Clinical Trials, Pre-2019-2023
Table 10.1 RNA Therapeutics and RNA Vaccines: List of Filed / Granted Patents, 2019-2023
Table 11.1 RNA Therapeutics and RNA Vaccines: List of Partnerships and Collaborations, 2019-2023
Table 12.1 RNA Therapeutics and RNA Vaccines: List of Funding and Investments, 2019-2023
Table 13.1 RNA Therapeutics and RNA Vaccines: List of Big Pharma Initiatives, 2019-2023
Table 14.1 RNA Therapeutics and RNA Vaccines Market: Expected Launch Year of Forecasted Drug Candidates
Table 22.1 Next Generation RNA Therapies: Distribution by Type of Modality
Table 22.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Table 22.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Table 22.4 Next Generation RNA Therapies: Distribution by Phase of Development
Table 22.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Table 22.6 Most Active Players: Distribution by Number of Therapies
Table 22.7 Clinical Stage Therapies: Distribution by Phase of Development
Table 22.8 Clinical Stage Therapies: Distribution by Route of Administration
Table 22.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Table 22.10 Therapy Developer Landscape: Distribution by Year of Establishment
Table 22.11 Therapy Developer Landscape: Distribution by Company Size
Table 22.12 Therapy Developer Landscape: Distribution by Location of Headquarters
Table 22.13 circRNA Therapies: Distribution by Phase of Development
Table 22.14 circRNA Therapies: Distribution by Therapeutic Area
Table 22.15 Most Active Players: Distribution by Number of circRNA Therapies
Table 22.16 saRNA Therapies: Distribution by Phase of Development
Table 22.17 saRNA Therapies: Distribution by Therapeutic Area
Table 22.18 Most Active Players: Distribution by Number of saRNA Therapies
Table 22.19 Next Generation RNA Technologies: Distribution by Class of Molecule
Table 22.20 Next Generation RNA Technologies: Distribution by Type of Molecule
Table 22.21 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Table 22.22 Next Generation RNA Technologies: Distribution by Therapeutic Area
Table 22.23 Next Generation RNA Technologies: Distribution by Highest Phase of Development
Table 22.24 Technology Developer Landscape: Distribution by Year of Establishment
Table 22.25 Technology Developer Landscape: Distribution by Company Size
Table 22.26 Technology Developer Landscape: Distribution by Location of Headquarters
Table 22.27 Technology Developer Landscape: Distribution by Operational Model
Table 22.28 Gemcovac®: Estimated Sales
Table 22.29 ATYR1923: Estimated Sales
Table 22.30 ARCT-154: Estimated Sales
Table 22.31 GRT-C901: Estimated Sales
Table 22.32 VLPCOV-01: Estimated Sales
Table 22.33 AVX901: Estimated Sales
Table 22.34 MTL-CEBPA + Sorafenib: Estimated Sales
Table 22.35 SLATE: Estimated Sales
Table 22.36 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
Table 22.37 Clinical Trial Analysis: Distribution by Trial Status
Table 22.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
Table 22.39 Clinical Trial Analysis: Distribution by Trial Phase
Table 22.40 Clinical Trial Analysis: Distribution by Patients Enrolled
Table 22.41 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 22.42 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 22.43 Clinical Trial Analysis: Distribution by Study Design
Table 22.44 Leading Organizations: Distribution by Number of Trials
Table 22.45 Clinical Trial Analysis: Distribution by Focus Area
Table 22.46 Clinical Trial Analysis: Distribution by Geography
Table 22.47 Patent Analysis: Distribution by Type of Patent
Table 22.48 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
Table 22.49 Patent Analysis: Distribution by Patent Jurisdiction
Table 22.50 Patent Jurisdiction: North American Scenario
Table 22.51 Patent Jurisdiction: European Scenario
Table 22.52 Patent Jurisdiction: Aisa-Pacific Scenario
Table 22.53 Patent Analysis: Distribution by Patent Age
Table 22.54 Patent Analysis: Distribution by CPC Symbols
Table 22.55 Leading Industry Players: Distribution by Number of Patents
Table 22.56 Leading Non-Industry Players: Distribution by Number of Patents
Table 22.57 Patent Analysis: Distribution by Patent Characteristics
Table 22.58 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
Table 22.59 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 22.60 Partnerships and Collaborations: Distribution by Type of Partnership
Table 22.61 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
Table 22.62 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
Table 22.63 Partnerships and Collaborations: Distribution by Focus of Partnership
Table 22.64 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 22.65 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 22.66 Most Active Players: Distribution by Number of Partnerships
Table 22.67 Partnerships and Collaborations: Local and International Deals
Table 22.68 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 22.69 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
Table 22.70 Funding and Investment Analysis: Distribution by Type of Funding
Table 22.71 Funding and Investment Analysis: Distribution by Type of Molecule
Table 22.72 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
Table 22.73 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 22.74 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Table 22.75 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
Table 22.76 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 22.77 Funding and Investment Analysis: Distribution by Stage of Development
Table 22.78 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 22.79 Most Active Players: Distribution by Number of Funding Instances
Table 22.80 Most Active Players: Distribution by Amount Invested (USD Million)
Table 22.81 Leading Investors: Distribution by Number of Funding Instances
Table 22.82 Big Pharma Initiatives: Distribution by Number of Initiatives
Table 22.83 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2019-2023
Table 22.84 Big Pharma Initiatives: Distribution by Type of Initiative
Table 22.85 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
Table 22.86 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
Table 22.87 Big Pharma Initiatives: Distribution by Focus of Initiative
Table 22.88 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
Table 22.89 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
Table 22.90 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
Table 22.91 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
Table 22.92 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
Table 22.93 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.94 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.95 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
Table 22.96 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.97 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.98 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.99 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.100 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
Table 22.101 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
Table 22.102 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
Table 22.103 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
Table 22.104 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
Table 22.105 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
Table 22.106 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Table 22.107 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Table 22.108 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
Table 22.109 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Table 22.110 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
Table 22.111 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
Table 22.112 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
Table 22.113 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
Table 22.114 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
Table 22.115 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
Table 22.116 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
Table 22.117 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
Table 22.118 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
Table 22.119 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
Table 22.120 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
Table 22.121 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
Table 22.122 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://www.biospace.com/article/releases/esperovax-and-ginkgo-bioworks-announce-partnership-to-develop-circular-rna-based-therapeutics/
Source 2: https://www.hdt.bio/news-blog/hdt-bio-to-develop-rna-cancer-vaccines-and-treatments-with-south-africas-pan-african-cancer-research-institute-pacri
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES